| Vol. 13.31 – 26 August, 2021 |
| |
|
|
| The authors reported a stromal cell-free, microbead-based approach that supported the efficient in vitro development of both human progenitor T cells and T-lineage cells from CD34+ cells sourced from cord blood, GCSF-mobilized peripheral blood, and pluripotent stem cells. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists hypothesized that S100A9, as major alarmin, were associated with the pathogenesis of preeclampsia and induction of a preeclampsia-like phenotype in pregnant mice. [Journal of Hypertension] |
|
|
|
| The human umbilical cord MSC exosomes were found to effectively improve the viability of nucleus pulposus cells and protect them from pyroptosis through targeting METTL14, with a methyltransferase catalyzing m6A modification. [Molecular Medicine] |
|
|
|
| Investigators showed that intramuscular injection of placental (P)-MSCs homed more towards the visceral site, restored HOMA-IR and glucose homeostasis in the WNIN/GR-Ob rats. P-MSC therapy was effective in re-establishing the dysregulated cytokines. [Scientific Reports] |
|
|
|
| Scientists examined the healing mechanisms in amniotic membrane (AM) defects after trauma. Traumatised human AM defects were cultured for four days. [Scientific Reports] |
|
|
|
| Researchers determined whether human umbilical cord-derived-MSCs-exosomes had a hepatoprotective effect on non-alcoholic fatty liver disease. [Human Cell] |
|
|
|
| Investigators used in vitro transport studies in Transwell®, in combination with their maternal-fetal physiologically based pharmacokinetic model, to predict fetal Kp,uu of drugs that were effluxed by placental P-glycoprotein. [Drug Metabolism and Disposition] |
|
|
|
|
| The authors discuss how TORCH pathogens access the intra-amniotic space and overcome the placental defences that protect against microbial vertical transmission. [Nature Reviews Microbiology] |
|
|
|
|
| Bonus BioGroup LTD, has received official approval from the Israeli Ministry of Health to expand its phase II clinical trials for its MesenCure treatment to health centers and hospitals nationwide. MesenCure leverages advances in cell therapy to treat COVID-19 patients suffering from life-threatening pneumonia, acute respiratory distress, and associated complications caused by the immune system’s hyper-inflammatory response to the virus. [Bonus BioGroup LTD (GlobeNewswire, Inc.)] |
|
|
|
|
|
|
|
| Indiana University – Indianapolis, Indiana, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Michigan State University – East Lansing, Michigan, United States |
|
|
|
| UCLA Jules Stein Eye Institute – Los Angeles, California, United States |
|
|
|
| Danaher – Toronto, Ontario, Canada |
|
|
|
|